文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

重塑肿瘤相关中性粒细胞以增强基于树突状细胞的 HCC 新抗原纳米疫苗效率。

Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.

机构信息

The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, P. R. China.

Mengchao Med-X Center, Fuzhou University, Fuzhou, 350116, P. R. China.

出版信息

Adv Sci (Weinh). 2022 Apr;9(11):e2105631. doi: 10.1002/advs.202105631. Epub 2022 Feb 10.


DOI:10.1002/advs.202105631
PMID:35142445
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9009112/
Abstract

Hepatocellular carcinoma (HCC) commonly emerges in an immunologically "cold" state, thereafter protects it away from cytolytic attack by tumor-infiltrating lymphocytes, resulting in poor response to immunotherapy. Herein, an acidic/photo-sensitive dendritic cell (DCs)-based neoantigen nano-vaccine has been explored to convert tumor immune "cold" state into "hot", and remodel tumor-associated neutrophils to potentiate anticancer immune response for enhancing immunotherapy efficiency. The nano-vaccine is constructed by SiPCCl -hybridized mesoporous silica with coordination of Fe(III)-captopril, and coating with exfoliated membrane of matured DCs by H22-specific neoantigen stimulation. The nano-vaccines actively target H22 tumors and induce immunological cell death to boost tumor-associated antigen release by the generation of excess O through photodynamic therapy, which act as in situ tumor vaccination to strengthen antitumor T-cell response against primary H22 tumor growth. Interestingly, the nano-vaccines are also home to lymph nodes to directly induce the activation and proliferation of neoantigen-specific T cells to suppress the primary/distal tumor growth. Moreover, the acidic-triggered captopril release in tumor microenvironment can polarize the protumoral N2 phenotype neutrophils to antitumor N1 phenotype for improving the immune effects to achieve complete tumor regression (83%) in H22-bearing mice and prolong the survival time. This work provides an alternative approach for developing novel HCC immunotherapy strategies.

摘要

肝细胞癌 (HCC) 通常出现在免疫“冷”状态,此后它会保护自己免受肿瘤浸润淋巴细胞的细胞溶解攻击,导致对免疫治疗的反应不佳。在此,研究了一种基于酸性/光敏感树突细胞 (DC) 的新型抗原纳米疫苗,以将肿瘤免疫“冷”状态转化为“热”状态,并重塑肿瘤相关中性粒细胞,增强抗癌免疫反应,提高免疫治疗效率。该纳米疫苗由 SiPCCl 杂化介孔硅与 Fe(III)-卡托普利配位而成,并通过 H22 特异性新抗原刺激成熟 DC 的剥落膜进行涂层。纳米疫苗主动靶向 H22 肿瘤,并通过光动力疗法产生过量 O,诱导免疫细胞死亡,从而增强肿瘤相关抗原的释放,作为原位肿瘤疫苗,增强针对原发性 H22 肿瘤生长的抗肿瘤 T 细胞反应。有趣的是,纳米疫苗还存在于淋巴结中,直接诱导新抗原特异性 T 细胞的激活和增殖,抑制原发性/远端肿瘤的生长。此外,肿瘤微环境中酸性触发的卡托普利释放可以将促肿瘤 N2 表型中性粒细胞极化为抗肿瘤 N1 表型,以提高免疫效果,实现 H22 荷瘤小鼠的完全肿瘤消退 (83%) 并延长生存时间。这项工作为开发新型 HCC 免疫治疗策略提供了一种替代方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/eff4e2edc5a5/ADVS-9-2105631-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/28cd975f7d64/ADVS-9-2105631-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/0410671a6d09/ADVS-9-2105631-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/6dc86165fe53/ADVS-9-2105631-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/be88b380cc61/ADVS-9-2105631-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/e8071fc9f75d/ADVS-9-2105631-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/eff4e2edc5a5/ADVS-9-2105631-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/28cd975f7d64/ADVS-9-2105631-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/0410671a6d09/ADVS-9-2105631-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/6dc86165fe53/ADVS-9-2105631-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/be88b380cc61/ADVS-9-2105631-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/e8071fc9f75d/ADVS-9-2105631-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a805/9009112/eff4e2edc5a5/ADVS-9-2105631-g003.jpg

相似文献

[1]
Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency.

Adv Sci (Weinh). 2022-4

[2]
Caveolin-mediated cytosolic delivery of spike nanoparticle enhances antitumor immunity of neoantigen vaccine for hepatocellular carcinoma.

Theranostics. 2023

[3]
Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound.

World J Gastroenterol. 2010-7-28

[4]
Immunotherapeutic strategies for treatment of hepatocellular carcinoma with antigen-loaded dendritic cells: in vivo study.

Clin Exp Med. 2018-7-30

[5]
Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma.

Cancer Immunol Res. 2022-6-3

[6]
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.

Mol Cancer. 2021-12-13

[7]
STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.

J Exp Clin Cancer Res. 2017-11-7

[8]
Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma.

Ann Surg Oncol. 2016-12

[9]
Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.

Immunol Lett. 2016-9

[10]
Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.

J Hepatol. 2017-5-24

引用本文的文献

[1]
Targeting Glypican-3 for Liver Cancer Therapy: Clinical Applications and Detection Methods.

J Clin Transl Hepatol. 2025-8-28

[2]
Target neutrophil heterogeneity and plasticity in cancer.

J Hematol Oncol. 2025-8-12

[3]
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.

Chin Med J (Engl). 2025-9-5

[4]
Two-dimensional superlattice nanocatalysts unlock multimodal energy transformation-driven catalytic therapy.

Nat Commun. 2025-7-1

[5]
Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity.

Signal Transduct Target Ther. 2025-6-4

[6]
Unraveling the complex role of tumor-associated neutrophils within solid tumors.

Cancer Immunol Immunother. 2025-5-19

[7]
The miR-941/FOXN4/TGF-β feedback loop induces N2 polarization of neutrophils and enhances tumor progression of lung adenocarcinoma.

Front Immunol. 2025-4-25

[8]
Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma.

Exp Hematol Oncol. 2025-4-30

[9]
Drug delivery systems based on mesoporous silica nanoparticles for the management of hepatic diseases.

Acta Pharm Sin B. 2025-2

[10]
Targeting Antigen-Presenting Cells to Enhance the Tumor-Spleen Immunity Cycle through Liposome-Neoantigen Vaccine.

Adv Sci (Weinh). 2025-5

本文引用的文献

[1]
Personalized neoantigen vaccine prevents postoperative recurrence in hepatocellular carcinoma patients with vascular invasion.

Mol Cancer. 2021-12-13

[2]
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.

J Clin Oncol. 2021-9-20

[3]
RBC Membrane Camouflaged Semiconducting Polymer Nanoparticles for Near-Infrared Photoacoustic Imaging and Photothermal Therapy.

Nanomicro Lett. 2020-4-20

[4]
Tumor-Associated-Macrophage-Membrane-Coated Nanoparticles for Improved Photodynamic Immunotherapy.

Nano Lett. 2021-7-14

[5]
Cell/Bacteria-Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy.

Adv Mater. 2021-12

[6]
Therapeutic cancer vaccines.

Nat Rev Cancer. 2021-6

[7]
Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity.

Adv Sci (Weinh). 2021-1-29

[8]
Immune Cell Membrane-Coated Biomimetic Nanoparticles for Targeted Cancer Therapy.

Small. 2021-3

[9]
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.

Nat Rev Gastroenterol Hepatol. 2021-5

[10]
Hepatocellular carcinoma.

Nat Rev Dis Primers. 2021-1-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索